Peptide inhibitors have also been used to downregulate translation e.g., BL22, an immunotoxin developed for the treatment of Chronic Lymphocytic Leukemia (CLL) [60], consists of the variable FV fragment of the RFB4 antibody conjugated to the anti-translation peptide PE38. Here, F5 is linked to B-cell chronic lymphocytic leukemia.